ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0931

Oropharyngeal Dysfunction in Patients with Systemic Sclerosis – Results of a Monocentric Clinical Study

Philipp Klemm1, Mirjam Wirths2, Ole Hudowenz2, Ulrike Hoffmann3, Ulf Müller-Ladner2 and Uwe Lange2, 1Department of Rheumatology, Immunology, Osteology and Physical Medicine, Justus Liebig University Gießen, Campus Kerckhoff, Bad Nauheim, Germany, Bad Nauheim, Hessen, Germany, 2Department of Rheumatology, Immunology, Osteology and Physical Medicine, Justus Liebig University Gießen, Campus Kerckhoff, Bad Nauheim, Germany, Bad Nauheim, Germany, 3Practice for Speech Therapy Ulrike Hoffmann, Friedberg, Germany

Meeting: ACR Convergence 2020

Keywords: physical function, physical therapy, Scleroderma, Systemic, Systemic sclerosis

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 7, 2020

Title: Systemic Sclerosis & Related Disorders – Clinical Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Nearly 98% of patients with systemic sclerosis (SSc) are suffering from gastrointestinal involvement (Schmeiser et al. 2012). While in everyday clinical practice screening for reflux and gastrointestinal dysmotility is part of the routine procedure and evidence-based treatment options exist (Mercado et al. 2005; Boeckxstaens et al. 2002), screening for oropharyngeal dysfunction is rarely done nor adequately treated. In 2012, a study of the German Network of Systemic Scleroderma (DNSS) showed, that about 78% of patients reported hoarseness and/or chronic cough. As oropharyngeal dysfunction (e.g. voice dysfunction, dysphagia) can significantly affect quality-of-life and lead to social stigmatization, we initiated a study (DRKS00020776) to address this problem.

Methods: We examined patients with systemic sclerosis using a self-constructed questionnaire and a standardized logopedic examination for signs and symptoms of oropharyngeal dysfunction (e.g., speech disorder, voice disorder, reflux, dysphagia), restrictions of the oropharyngeal musculature (palate, tongue, mimic musculature) and breathing disorders. If any of these were positive, oropharyngeal dysfunction was diagnosed. Furthermore, we analysed, if these findings were associated with specific disease characteristics.

Results: Of 55 patients with SSc fulfilling the inclusion criteria, 55 patients agreed to screening for oropharyngeal dysfunction (medical history and physical examination).

43 out of 55 (78%) SSc patients described at least one symptom of oropharyngeal dysfunction: dysphagia (72%), reflux (67%) and/or voice disorder (16%). In physical examination, 43 out of 55 (78%) patients showed also an oropharyngeal dysfunction.

Neither the subtyp of SSc (d/lcSSc) nor the extent of skin fibrosis (mRSS) were significantly associated with the manifestation of oropharyngeal dysfunction. In contrast, a statistically significant relationship between duration of illness and the manifestation of oropharyngeal dysfunction could be found.

26 out 55 patients received an additional logopedic examination. Of these, 26 out of 26 patients (100%) showed to have at least one type of oropharyngeal dysfunction (table 1). Most striking was the altered function (limitation) of oropharyngeal musculature in 25 out of 26 (96%) cases.

Conclusion: Although it is known that nearly all patients with SSc have an involvement of at least one part of the gastrointestinal tract, examination for oropharyngeal dysfunction is rarely done. The data of our study indicate, that independently of the subtype of SSc, this complication is more frequent than expected, increases with the duration of the disease and should therefore be implemented in the standard routine diagnostics for SSc.

Frequency und type of oropharyngeal dysfunction

Influencing factors


Disclosure: P. Klemm, MEDAC, 5, Novartis, 5, Eli Lilly, 5, Gilead, 5; M. Wirths, None; O. Hudowenz, None; U. Hoffmann, None; U. Müller-Ladner, Biogen, 8; U. Lange, None.

To cite this abstract in AMA style:

Klemm P, Wirths M, Hudowenz O, Hoffmann U, Müller-Ladner U, Lange U. Oropharyngeal Dysfunction in Patients with Systemic Sclerosis – Results of a Monocentric Clinical Study [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/oropharyngeal-dysfunction-in-patients-with-systemic-sclerosis-results-of-a-monocentric-clinical-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/oropharyngeal-dysfunction-in-patients-with-systemic-sclerosis-results-of-a-monocentric-clinical-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology